|
|
|
A potential barrier to the therapeutic use of human embryonic stem cells appears to be less of a concern than previously thought, according to a study published in the June 2005 issue of Nature Genetics. Peter Rugg-Gunn and colleagues report that the status of so-called 'imprinted' genes, in which only one copy of the gene is expressed, is generally normal in a sampling of such genes in a series of human stem cell lines grown in culture dishes.
Previous work had shown that imprinted genes in embryonic stem cells generated from mouse embryos had altered expression patterns. As such aberrant gene expression might affect the viability or proper functioning of the cells when introduced into individuals as a replacement for diseased cells, it was feared that this represented a major obstacle to their therapeutic use. Rugg-Gunn and colleagues examined six genes and three other regions of the human genome that are involved in imprinting -- all but one of which had the normal pattern of expression in the human stem cell lines. Although they note that it is possible that the expression of other genes might be altered in human embryonic stem cells, the current work suggests a greater degree of stability than anticipated. Author Contact: Peter Rugg-Gunn (University of Cambridge, UK)
E-mail: pjr36@cam.ac.uk Online version of publication available here. (C) Nature Genetics press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|